Advice
following an abbreviated submission:
latanoprost plus timolol (Fixapost®) is accepted for restricted use within NHSScotland.
Indication under review: reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
SMC restriction: to use in patients who have proven sensitivity to preservatives.
The combination product costs less than preservative-free latanoprost and timolol eye drops administered separately but is more expensive than the equivalent generic multi-dose eye drop preparation with preservative.
Download detailed advice361KB (PDF)
Medicine details
- Medicine name:
- latanoprost + timolol (Fixapost)
- SMC ID:
- SMC2159
- Indication:
- Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
- Pharmaceutical company
- Thea Pharmaceuticals
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 13 May 2019